Blood Disorder TRIZ Cases
- RSK and CHK2 Inhibitors for Diamond Blackfan Anemia Rescue
Targeting RSK, Chk2, and related pathways raises hemoglobin and restores erythroid differentiation in ribosomal protein deficient cells.
- LRRC8 Channel Modulation for Platelet Thrombosis Control
Targeting LRRC8 channels with modulators such as DCPIB inhibits platelet activation and thrombosis while limiting bleeding risk.
- Surface CALR Chemical Inducers for HSC Quality Control
ROS-inducing CALR agonists regulate macrophage–HSC interactions to remove damaged stem cells while supporting healthy HSC proliferation.
- High-Affinity Thrombin Aptamers for Targeted Thrombin Inhibition
Thrombin-specific aptamers inhibit enzymatic activity with high affinity while addressing bleeding risks and drug interactions linked to DOACs.
- Mutated FIX Proteins for Hemophilia B Treatment
Engineered recombinant factor IX variants with targeted mutations extend half-life and reduce dosing frequency for hemophilia B treatment.
- Hydroxyfasudil Rho-kinase Inhibition for Sickle Cell Disease
Hydroxyfasudil induces HbF via Rho-kinase inhibition, avoiding Hydroxyurea DNA damage.
- Rivaroxaban Dosing Adjustment for Verapamil Interaction
Segmenting patients by renal function to reduce rivaroxaban doses when co-administered with verapamil, preventing excessive drug exposure and bleeding risk.
- Glycosaminoglycan Sulfation in Strongly Basic Aqueous Media
Sulfating glycosaminoglycans using strongly basic aqueous solutions without organic solvents.
- Amino Acid Composition for Coagulation Dysfunction in MODS
L-ornithine, aspartic acid, arginine, and vitamin B6 support intrinsic coagulation pathways to restore liver function.
- VHH Antibody Plasmin Binding Fibrinolysis
VHH antibodies bind plasmin to accelerate generation and enhance fibrin degradation, countering rapid inactivation by alpha-2-antiplasmin.
- ZNF622 Targeting for Ribosomal Dysfunction in Stem Cells
Synthetic nucleic acid molecules reduce ZNF622 expression to enhance ribosomal subunit joining and protein synthesis in human stem cells.
- dsRNA Agents Targeting Coagulation Factor X mRNA
dsRNA agents degrade coagulation Factor X mRNA via RNA interference, reducing thrombosis risk without causing excessive bleeding.
- Macitentan Inhibits ITGA9-VCAM1 Binding to Prevent Thrombosis
Macitentan blocks integrin alpha9 binding to VCAM-1, preventing thrombus formation without increasing bleeding risks.
- Tandem shmiR Constructs for Fetal Hemoglobin Induction
Tandem shmiR constructs suppress BCL11A and ZNF-410 to increase fetal hemoglobin, addressing limited efficacy of hydroxyurea.
- pH-Sensitive Anti-TFPI Antibody Variant for Hemophilia Treatment
Engineered antibody variant dissociates from TFPI at endosomal pH 6.0 to enable FcRn-mediated recycling.
- CFTR Modulators Attenuate Thrombocyte Activation
Ivacaftor attenuates thrombocyte activation to reduce morbidity from inadequate conventional treatments.
- Pelabresib BET Inhibition for Anemia Reticulocyte Production
Pelabresib overcomes inadequate red blood cell production by inhibiting BET proteins, increasing reticulocyte counts and resolving treatment effectiveness gaps.